Shanghai Chicmax Cosmetic signs strategic cooperation agreement with Suzhou Kintor for KT-939 commercialization

Reuters03-17
Shanghai Chicmax Cosmetic signs strategic cooperation agreement with Suzhou Kintor for KT-939 commercialization

Shanghai Chicmax Cosmetic said it entered a strategic cooperation framework agreement with Suzhou Kintor, a unit of Kintor Pharmaceutical, covering the cosmetics field under an exclusivity clause. The parties will work on registering KT-939 as a new cosmetic ingredient in China and on registering cosmetic products that use KT-939 as a core ingredient. They also plan joint R&D and customization work related to KT-939, which is described as a whitening and freckle-removing ingredient.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Chicmax Cosmetic Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260317-12056110), on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment